Source: Yantai Daily - Big and Small News
From July 29 to 30, the 2021 International Conference on Pharmaceutical Innovation and Development was successfully held in Yantai. Well-known pharmaceutical industry experts and scholars from all over the world and at home and abroad gathered to discuss the new future of the pharmaceutical industry and seek high-quality development of the pharmaceutical industry.
As the "highlight" of this international conference, the third ADC New Drug Creation Seminar was also held as scheduled. Dr. Song Haifeng, Director of the National Engineering Research Center for Protein Drugs, Dr. Cao Guoqing, CEO of Minghui Pharmaceutical, Dr. Zhao Yongxin, President of Duoxi Biology, Dr. Cai Jiaqiang, Chief Scientific Officer of Suzhou Yilian Biology, Dr. Xie Yansheng, Senior Vice President of Zhejiang Trisy Pharmaceutical, Dr. Miao Zhenwei, Founder and CEO of Hangzhou Imperient, Dr. Qin Minmin, Senior Vice President of Lepu Biologics, Dr. He Ruyi, Chief Medical Officer of Rongchang Biology, Dr. Fu Daotian, President of Rongchang Biology, Dr. Jiang Jing, Vice President of Rongchang Biology, Dr. Xinfang Li, President of Macbury, and Dr. Changjiang Huang, Chief Scientific Officer, attended the meeting with more than ten top experts in the field of ADC in China.
Experts and scholars discussed how to collaborate on innovation to accelerate the development and industrialization of ADCs.
At the meeting, the big names in the ADC (Antibody Drug Conjugate) industry conducted an accurate analysis of the current progress and forward-looking direction of the ADC industry, and conducted in-depth discussions on how to link innovation to promote the speed of ADC drug research and development. As the top CDMO company in the field of ADC in China, McBlare not only has the full chain service system of ADC drugs, but also has rich experience in ADC project research and development and CMC, which became the focus of the seminar.
In recent years, with the continuous improvement of biological and chemical drug research technology, the field of antibody-conjugated drugs (ADCs) has once again burst into vitality. The concept of ADC drugs has emerged as early as the 1960s, as of now, more than 10 ADC drugs have been approved for marketing worldwide, and since 2019 alone, 5 new ADC drugs have been listed in different countries and regions. The industry predicts that according to the current development status of the ADC drug market, the ADC drug market size is expected to exceed $16.4 billion by 2026.
The picture shows a corner of the Macberry workshop.
At the same time, the data shows that in 2019, there were nearly 200 ADC drugs in the world, and in the first quarter of 2020 alone, this number climbed to more than 300, of which the number of Chinese ADC product research and development ranked second in the world after the United States.
Obviously, the ADC field has begun an explosive development stage, but due to the limitation of the target, the speed of drug research is also the key to the success of ADC drug development companies. Taking advantage of the rich experience of CDMO companies, the perfect GMP system is undoubtedly the best choice.
In the roundtable discussion on "collaborative innovation, accelerating ADC research and development and industrialization" in this forum, the participating experts said: Through joint development, professional things are left to professionals. The CDMO model is very suitable for start-ups, from early research and development, to clinical drugs, commercial production, CDMO model can provide support for the whole industry chain.
Dr. Cai Jiaqiang, chief scientific officer of Suzhou Yilian Biology, said: "Making medicine is a very complicated process, and ADC is even more complicated. From discovery to final listing, purely doing it yourself is not the optimal solution. Innovative things are done by themselves, and others are achieved through "take-ism" as better solutions. McBury, which is committed to providing CDMO services to pharmaceutical companies around the world, has exactly what pharmaceutical companies need to "take".
The participating experts agreed with the linkage efficiency between enterprises and CDMO suppliers, the era of accelerated racing in the ADC field, time to market is the key to victory, and choosing CDMO is the most "reliable" choice whether it is considered from time or cost. For example, handed over to a company like Macbury, from research and development to production can achieve one-stop service, quickly help enterprises to launch products.
Qin Minmin, senior vice president of Lepu Biology, believes that innovative pharmaceutical companies should still be product-oriented, ADCs have complex structures, antibodies, small molecules, and its development process and preparations are more complex than other biological drugs. "We also plan to find suitable CDMO companies in the commercial production phase." He said.
"Let professional people and companies do professional things." In foreign countries, most companies are using CDMO to do commercial production, in China, Macbrune is relatively leading in this regard, whether it is ADC or small molecules can do. Macbury's resources and experience will play a role in accelerating the declaration or accelerating the listing of new drugs in enterprises, and ultimately solve the needs of our patients, provide doctors with therapeutic weapons, and provide people with better opportunities to survive. One panelist saw the relationship between companies and CDMO in a roundtable forum.
In this conference, it has been hotly discussed by participating experts, what hard power does McBriel have? Does it have the ability to be a good partner for biopharmaceutical companies on their way to marketing new products?
Macbriam is one of the few companies in the world that can provide ADC drugs from R&D to commercial production. Connecton technology with proprietary intellectual property rights can improve treatment windows and reduce non-specific cytotoxicity, accelerating the development of ADC drugs.
With a 150-liter coupling scale, ADC can provide 400 grams of Linker-Toxin (based on MMAE) commercial production, and is one of the few biomedical CDMO companies in the industry with its own antibody and ADC preparation line. According to relevant data, at present, McBly has provided services for more than half of the ADC projects that have obtained clinical trial approvals and used CDMO in China.
Macbriam continues to explore innovative technologies and successfully solve many key technical problems for customers, and has been recognized by the industry, and has won the 2019 Frost & Sullivan ADC Drug CMO Global Growth Excellence Leadership Award, IMAPAC Greater China Antibody and ADC Manufacturing Process Excellence Award and other honors. The company's innovation ability and technology transformation ability have also been highly recognized and supported by the government, and have been rated as "National High-tech Enterprise" and "Gazelle Enterprise of Shandong Province".
Dr. Li Xinfang, President of Macbury, said at the forum: Macbria has accumulated rich successful experience in process development, process amplification to large-scale production in the field of ADC, and has established a mature CMC management and registration declaration system, which can help customers take fewer detours, minimize costs, and greatly accelerate the listing speed of ADC drugs.
YMG reporter Gao Shaoshuai photo report
This article is from [Yantai Daily - Big and Small News] and only represents the author's views. The National Party Media Information Public Platform provides information dissemination services.
ID：jrtt